We are live on ! Find out more
NYLIM

New York Life Investment Management Portfolio holdings

AUM $14.3B
1-Year Est. Return 34.42%
This Fund
S&P 500
This Quarter Est. Return
+7.44%
1 Year Est. Return
+34.42%
3 Year Est. Return
+100.17%
5 Year Est. Return
+116.66%
10 Year Est. Return
+182.12%
AUM
$9.61B
AUM Growth
+$620M
Cap. Flow
+$78.9M
Cap. Flow %
0.82%
Top 10 Hldgs %
26.27%
Holding
1,380
New
183
Increased
256
Reduced
860
Closed
74
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INVA icon
776
Innoviva
INVA
$1.5B
$466K ﹤0.01%
36,634
-5,735
-14% -$71.8K
INSP icon
777
Inspire Medical Systems
INSP
$1.68B
$466K ﹤0.01%
+1,435
New +$410K
MITK icon
778
Mitek Systems
MITK
$853M
$466K ﹤0.01%
42,975
-7,122
-14% -$69.6K
FIX icon
779
Comfort Systems
FIX
$60.8B
$464K ﹤0.01%
2,826
-456
-14% -$67.8K
BASE
780
DELISTED
Couchbase
BASE
$464K ﹤0.01%
29,313
-4,995
-15% -$81.7K
PRO
781
DELISTED
PROS Holdings
PRO
$463K ﹤0.01%
15,041
-2,956
-16% -$83.1K
HY icon
782
Hyster-Yale Materials Handling
HY
$617M
$461K ﹤0.01%
8,261
-1,424
-15% -$72.8K
GEF icon
783
Greif
GEF
$5.03B
$461K ﹤0.01%
6,694
-882
-12% -$56.6K
IIIN icon
784
Insteel Industries
IIIN
$634M
$461K ﹤0.01%
14,814
-2,167
-13% -$64.2K
ANDE icon
785
Andersons Inc
ANDE
$2.21B
$461K ﹤0.01%
9,979
-1,383
-12% -$57.9K
CASH icon
786
Pathward Financial
CASH
$1.79B
$460K ﹤0.01%
9,933
-1,592
-14% -$71.4K
AVIR icon
787
Atea Pharmaceuticals
AVIR
$406M
$460K ﹤0.01%
123,025
-22,334
-15% -$83.6K
RCUS icon
788
Arcus Biosciences
RCUS
$3.67B
$459K ﹤0.01%
22,595
-3,578
-14% -$68.1K
RGA icon
789
Reinsurance Group of America
RGA
$16.4B
$459K ﹤0.01%
+3,307
New +$470K
RUSHA icon
790
Rush Enterprises Class A
RUSHA
$9.62B
$458K ﹤0.01%
11,322
-1,901
-14% -$69.7K
ALNY icon
791
Alnylam Pharmaceuticals
ALNY
$30.4B
$458K ﹤0.01%
2,413
-90
-4% -$17.8K
SAIA icon
792
Saia
SAIA
$10.1B
$458K ﹤0.01%
+1,338
New +$387K
ALKS icon
793
Alkermes
ALKS
$8.3B
$458K ﹤0.01%
14,633
-2,287
-14% -$69.2K
SPNT icon
794
SiriusPoint
SPNT
$2.7B
$458K ﹤0.01%
50,693
-9,718
-16% -$88.9K
FBIN icon
795
Fortune Brands Innovations
FBIN
$5.78B
$457K ﹤0.01%
+6,358
New +$404K
CNX icon
796
CNX Resources
CNX
$5.23B
$456K ﹤0.01%
25,726
-4,079
-14% -$65.8K
DENN
797
DELISTED
Denny's
DENN
$455K ﹤0.01%
36,930
-5,861
-14% -$66.5K
FA icon
798
First Advantage
FA
$3.81B
$455K ﹤0.01%
29,522
-3,841
-12% -$51.5K
BDC icon
799
Belden
BDC
$5.36B
$454K ﹤0.01%
4,750
-840
-15% -$72K
ASTE icon
800
Astec Industries
ASTE
$975M
$454K ﹤0.01%
9,998
-1,727
-15% -$71.2K

Similar funds

New York Life Investment Management's Q2 2023 Portfolio in Review

As of Q2 2023, New York Life Investment Management held 1,380 positions worth $9.61B, up 6.9% from $8.99B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

New York Life Investment Management's Q2 2023 filing shows 183 new, 256 increased, 860 reduced and 74 closed positions. Its largest new stake was JPMorgan Equity Premium Income ETF: 826,750 shares worth $45.7M. The largest sale was Vanguard Short-Term Corporate Bond ETF, an estimated $108M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.

  • New York Life Investment Management's largest Q2 2023 buy was JPMorgan Equity Premium Income ETF: 826,750 shares worth $45.7M.
  • New York Life Investment Management added most to iShares Floating Rate Bond ETF in Q2 2023, an estimated $136M increase.
  • New York Life Investment Management's biggest Q2 2023 reduction was IQ Candriam US Large Cap Equity ETF, cutting an estimated $35.8M.
  • New York Life Investment Management fully exited Vanguard Short-Term Corporate Bond ETF in Q2 2023, selling an estimated $108M.
  • New York Life Investment Management's ten largest holdings make up 26% of its $9.61B portfolio in Q2 2023.
  • New York Life Investment Management opened 183 new positions and closed 74 in Q2 2023.
  • New York Life Investment Management's portfolio value rose 6.9% quarter-over-quarter to $9.61B.

Based on New York Life Investment Management's 13F filing for Q2 2023, filed 7 Aug 2023.